ASP Isotopes Inc.

ASPI

US00218A1051

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets 2026-01-21			5-day change	1st Jan Change
7.300 ^USD	+0.41%		-2.41%	+36.45%

Jan. 12	ASP Isotopes Inc. Announces Executive Appointments	CI
Jan. 07	ASP Isotopes Inc. completed the acquisition of Renergen Limited from Mazi Asset Management Ltd, Matc Investments Pty Ltd, CRT investments Pty. Ltd., Anchor Capital Ltd., Ivy Asset Management LLC, Ye Jia and others.	CI

ASP Isotopes announces Quantum Leap Energy's confidential submission of draft registration statement for IPO

Published on 11/12/2025 at 04:48 pm EST

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about ASP Isotopes Inc.

Jan. 12	ASP Isotopes Inc. Announces Executive Appointments	CI
Jan. 07	ASP Isotopes Inc. completed the acquisition of Renergen Limited from Mazi Asset Management Ltd, Matc Investments Pty Ltd, CRT investments Pty. Ltd., Anchor Capital Ltd., Ivy Asset Management LLC, Ye Jia and others.	CI
Jan. 07	Asp Isotopes closes acquisition of Renergen	RE
Dec. 30	ASX Midday Sector Update: Energy Stocks Climb, Real Estate Struggles	MT
Dec. 30	Renergen Securities Suspended From Quotation	MT
Dec. 17	Renergen, ASP Isotopes' Scheme of Arrangement Now Unconditional	MT
Dec. 17	ASP Isotopes Receives All Regulatory Approvals for Acquisition of Renergen	MT
Dec. 14	Certain Warrants of ASP Isotopes Inc. are subject to a Lock-Up Agreement Ending on 15-DEC-2025.	CI
Dec. 14	Certain Options of ASP Isotopes Inc. are subject to a Lock-Up Agreement Ending on 15-DEC-2025.	CI
Dec. 14	Certain Common Stock of ASP Isotopes Inc. are subject to a Lock-Up Agreement Ending on 15-DEC-2025.	CI
Dec. 02	Asp Isotopes Inc. Announces That Paul Mann to Return from Temporary Leave of Absence as Executive Chairman	CI
Dec. 02	Asp Isotopes Inc. Announces Paul Mann to Return from Temporary Leave of Absence as Chief Executive Officer, Effective January 19, 2026	CI
Dec. 02	ASP Isotopes Says Paul Mann to Resume CEO Role in January	MT
Dec. 02	Asp Isotopes Inc. announces Paul Mann to return from temporary leave of absence as executive chairman and CEO	RE
Nov. 28	Asp Isotopes Inc - on Nov 27, extended date for Renergen acquisition offer conditions - SEC filing	RE
Nov. 28	ASP Isotopes Extends Deadline to Meet Closing Conditions for Renergen Acquisition	MT
Nov. 19	ASP Isotopes Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 14	Certain Common Stock of ASP Isotopes Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2025.	CI
Nov. 14	Certain Options of ASP Isotopes Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2025.	CI
Nov. 14	Certain Warrants of ASP Isotopes Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2025.	CI
Nov. 12	ASP Isotopes announces Quantum Leap Energy's confidential submission of draft registration statement for proposed initial public offering	RE
Nov. 12	ASP Isotopes announces Quantum Leap Energy's confidential submission of draft registration statement for IPO	RE
Nov. 07	ASP Isotopes Subsidiary Launches $64.3 Million Private Offering of Convertible Notes	MT
Nov. 06	Quantum Leap Energy LLC announced that it expects to receive $64.3 million in funding from ASP Isotopes Inc., American Ventures Management LLC and other investors	CI
Nov. 05	ASP Isotopes Inc - Quantum Leap Energy begins early engagement with UK nuclear regulators	RE

ASP Isotopes Inc. is a development stage advanced materials company. The Company is engaged in the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (ASP technology). Its initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. Its Nuclear Fuels segment is focused on research and development of technologies and methods used to produce high-assay low-enriched uranium (HALEU) and Lithium-6 for the advanced nuclear fuels target end market. Its Specialist Isotopes and Related Services segment is focused on research and development of technologies and methods used to separate high-value, low-volume isotopes (such as C-14, Mo-100, and Si-28) for highly specialized target end markets other than advanced nuclear fuels, including pharmaceuticals and agrochemicals, nuclear medical imaging, and others.

Employees

136

Sector

Pharmaceuticals

More about the company